Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral ...

In a significant medical feat, Indian scientists have developed the first-in-human gene therapy using lentiviral vectors for ...

Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral ...

Current lentiviral vector systems (the third generation) generate virus particles using four plasmids and a producer cell line. The rationale behind four plasmids is to enhance safety, as ...

VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth ...

India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...

In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...

Download this application note from Thermo Fisher Scientific to learn how scientists have used their lentiviral production system, single-use bioreactors, and clarification products to generate ...

Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal ...

The “bottleneck” of current gene therapy approaches is the lack of an efficient gene delivery system. Retroviral vectors have been very useful for ex vivo gene delivery, but suffer two major ...